Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

By Dr. Matthew Watson

Geneva, Switzerland, February 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it completed 2020 with a strong cash position of CHF18.7 million of cash and cash equivalents.

Continued here:
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

Related Post


categoriaGlobal News Feed commentoComments Off on Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million | dataFebruary 17th, 2021

About...

This author published 3752 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research